GB0324897D0 - Composition - Google Patents

Composition

Info

Publication number
GB0324897D0
GB0324897D0 GB0324897A GB0324897A GB0324897D0 GB 0324897 D0 GB0324897 D0 GB 0324897D0 GB 0324897 A GB0324897 A GB 0324897A GB 0324897 A GB0324897 A GB 0324897A GB 0324897 D0 GB0324897 D0 GB 0324897D0
Authority
GB
United Kingdom
Prior art keywords
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0324897A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0324897A priority Critical patent/GB0324897D0/en
Publication of GB0324897D0 publication Critical patent/GB0324897D0/en
Priority to PCT/GB2004/004511 priority patent/WO2005041922A2/en
Ceased legal-status Critical Current

Links

GB0324897A 2003-10-24 2003-10-24 Composition Ceased GB0324897D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0324897A GB0324897D0 (en) 2003-10-24 2003-10-24 Composition
PCT/GB2004/004511 WO2005041922A2 (en) 2003-10-24 2004-10-22 Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0324897A GB0324897D0 (en) 2003-10-24 2003-10-24 Composition

Publications (1)

Publication Number Publication Date
GB0324897D0 true GB0324897D0 (en) 2003-11-26

Family

ID=29595798

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0324897A Ceased GB0324897D0 (en) 2003-10-24 2003-10-24 Composition

Country Status (2)

Country Link
GB (1) GB0324897D0 (en)
WO (1) WO2005041922A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609924A2 (en) * 2005-05-18 2010-05-11 Pulmatrix Inc use of an aerosol formulation containing about 0.5 to 20% (w / w) of a salt selected from the group consisting of a magnesium salt, a calcium salt, an aluminum salt, a silicon salt, a salt scandium, a titanium salt, a vanadium salt, a chrome salt, a cobalt salt, a nickel salt, a copper salt, a manganese salt, a zinc salt, a tin salt, and a combination thereof, and pharmaceutical composition
CN102497853B (en) 2009-03-26 2018-03-23 普马特里克斯营业公司 Treat the dry powder formulation and method of tuberculosis
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
EP2611438B1 (en) 2010-08-30 2020-04-01 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
RU2017144619A (en) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. CASES OF SINGLE-VALVE METALS OF DRY POWDERS FOR INHALATIONS
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
CN109999013A (en) 2012-02-29 2019-07-12 普马特里克斯营业公司 Inhalable dry powder doses
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
BR112017021111A2 (en) * 2015-04-01 2018-07-03 Lupin Atlantis Holdings Sa process for manufacturing dry powder mixtures
RU2715687C2 (en) * 2015-04-15 2020-03-02 Филип Моррис Продактс С.А. Powder inhaler and method for use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143440A (en) * 1966-07-21 1969-02-19 Merck & Co Inc Inhalation aerosol preparation
BR8007911A (en) * 1979-12-06 1981-06-16 Glaxo Group Ltd PERFECTED INHALER
SE448277B (en) * 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9115740D0 (en) * 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
DK1150918T3 (en) * 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Process for the preparation of therapeutic calcium phosphate particles
GB9911770D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Powder loading method

Also Published As

Publication number Publication date
WO2005041922A2 (en) 2005-05-12
WO2005041922A3 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
GB0305941D0 (en) Composition
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
EP1613352A4 (en) Micro-cluster compositions
GB0324897D0 (en) Composition
HK1087034A1 (en) Actacid composition
GB0322033D0 (en) Composition
GB0318824D0 (en) Novel composition
GB0305790D0 (en) Novel Composition
GB0329597D0 (en) Compositions
MY145151A (en) Composition
GB0300602D0 (en) Compositions
GB0309317D0 (en) Composition
GB0324295D0 (en) Composition
GB0306312D0 (en) Composition
GB0316857D0 (en) Compositions
GB0301869D0 (en) Composition
GB0326815D0 (en) Composition
GB0320018D0 (en) Composition
GB0320863D0 (en) Composition
GB0306315D0 (en) Composition
GB0311465D0 (en) Composition
GB0311810D0 (en) Composition
GB0304747D0 (en) Composition
GB0301669D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)